| Company Name: | ResMed Inc | | | Ticker Symbol: | RMD | | CIK Number: | 0000943819 | | WWW Address: | http://www.resmed.com |
| CEO: | Mr. Michael J. (Mike) Farrell | | No. of Employees: | 4,340 |
| Common Issue Type: | CS | | Business Description: | ResMed Inc. is a developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
|
| | | Industry Information: | HEALTH SERVICES - Medical Appliances & Equipment [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 63.25 |  -0.73 | - | - | 63.96 | 64.19 | 63.24 | 984372 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 8,899.3 | 140.7 | 0.00 | 2.51 | 1.32 | 25.9 | 1.9 | 70.90 - 49.11 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 63.25 | $ | | PE Ratio - LTM | 25.9 | |
| Market Capitalisation | 8,899.3 | mil |
| Latest Shares Outstanding | 140.7 | mil |
| Earnings pS (EPS) | 2.51 | $ |
| Dividend pS (DPS) | 1.32 | ¢ |
| Dividend Yield | 1.9 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 423,667 | $ |
| Effective Tax Rate | 0.2 | % |
| Float | 137.9 | mil |
| Float as % of Shares Outstanding | 1.0 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 0.30 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.10 | % |
| Gross Profit Margin | 58.0 | % |
| EBITDA Margin | 29.2 | % |
| Pre-Tax Profit Margin | 23.9 | % |
| Assets Turnover | 67.6 | % |
| Return on Assets (ROA) | 12.9 | % |
| Return on Equity (ROE) | 21.5 | % |
| Return on Capital Invested (ROCI) | 15.2 | % |
| Current Ratio | 2.2 | |
| Leverage Ratio (Assets/Equity) | 1.9 | |
| Interest Cover | 40.2 | |
| Total Debt/Equity (Gearing Ratio) | 0.69 | |
| LT Debt/Total Capital | 34.0 | % |
| Working Capital pS | 5.55 | $ |
| Cash pS | 0.00 | $ |
| Book-Value pS | 12.05 | $ |
| Tangible Book-Value pS | 2.39 | $ |
| Cash Flow pS | 3.87 | $ |
| Free Cash Flow pS | 3.39 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 5.35 | |
| Price/Tangible Book Ratio | 0.00 | |
| Price/Cash Flow | 16.7 | |
| Price/Free Cash Flow | 19.0 | |
| P/E as % of Industry Group | 104.0 | % |
| P/E as % of Sector Segment | 84.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | Cash Payment |
| Dividend Rate | 1.32 |
| Current Dividend Yield | 1.9 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -0.7 | -2 | 933,251 | 4,643,463 |
| 4 Weeks | 69.28 | 63.11 | 69.05 | -7.3 | -7 | 920,110 | 18,402,218 |
| 13 Weeks | 70.90 | 58.28 | 60.51 | 5.7 | -1 | 858,273 | 54,929,483 |
| 26 Weeks | 70.90 | 55.30 | 55.97 | 14.3 | 8 | 802,877 | 101,965,453 |
| 52 Weeks | 70.90 | 49.11 | 50.52 | 26.6 | 15 | 884,378 | 222,863,428 |
| YTD | 70.90 | 50.77 | - | 22.5 | 15 | 920,454 | 169,363,681 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 63.64 | 64.29 | 67.23 | 61.82 | 60.19 | 0.00 | 0.00 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.08 | 0.3 | 0.07 |
| Income | 0.09 | 0.3 | 0.05 |
| Dividend | | 0.4 | 0.21 |
| Capital Spending | 0.14 | NA | 0.11 |
| R&D | 15.95 | NA | 17.11 |
| Normalized Inc. | 22.42 | NA | 17.42 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 10.4 | 9.9 | 10.1 |
| Earnings % | 31.5 | 31.4 | 12.3 |
| EPS % | 35.6 | 31.8 | 18.8 |
| EPS $ | 0.42 | 0.14 | 0.27 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 23.97 |
| Current Ratio | 2.2 |
| Quick Ratio (Acid Test) | 0.0 |
| Liquidity Ratio (Cash) | 2.29 |
| Receivables Turnover | 4.9 |
| Average Collection Period | 73 |
| Working Capital/Equity | 46.1 |
| Working Capital pS | 5.56 |
| Cash-Flow pS | 3.47 |
| Free Cash-Flow pS | 3.00 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 5.05 |
| Financial Leverage Ratio (Assets/Equity) | 0.7 |
| Debt Ratio | 36.1 |
| Total Debt/Equity (Gearing Ratio) | 0.69 |
| LT Debt/Equity | 0.52 |
| LT Debt/Capital Invested | 32.3 |
| LT Debt/Total Liabilities | 74.5 |
| Interest Cover | 40.2 |
| Interest/Capital Invested | 0.43 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.00 |
| Tobin's Q Ratio | 2.78 |
| Current P/E Ratio - LTM | 25.90 |
| Enterprise Value (EV)/EBITDA | 17.06 |
| Enterprise Value (EV)/Free Cash Flow | 19.67 |
| Dividend Yield | 1.9 |
| Price/Tangible Book Ratio - LTM | 0.00 |
| Price/Book Ratio - LTM | 5.35 |
| Price/Cash Flow Ratio | 16.7 |
| Price/Free Cash Flow Ratio - LTM | 19.0 |
| Price/Sales Ratio | 0.00 |
| P/E Ratio (1 month ago) - LTM | 23.9 |
| P/E Ratio (26 weeks ago) - LTM | 22.3 |
| P/E Ratio (52 weeks ago) - LTM | 20.4 |
| 5-Y High P/E Ratio | 30.3 |
| 5-Y Low P/E Ratio | 9.4 |
| 5-Y Average P/E Ratio | 22.3 |
| Current P/E Ratio as % of 5-Y Average P/E | 31 |
| P/E as % of Industry Group | 104.0 |
| P/E as % of Sector Segment | 84.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 22.4 |
| PER SHARE FIGURES |
| LT Debt pS | 6.35 |
| Current Liabilities pS | 4.63 |
| Tangible Book Value pS - LTM | 2.39 |
| Book Value pS - LTM | 12.05 |
| Capital Invested pS | 20.40 |
| Cash pS - LTM | 0.00 |
| Cash Flow pS - LTM | 3.87 |
| Free Cash Flow pS - LTM | 3.39 |
| Earnings pS (EPS) | 2.51 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 26.11 |
| Free Cash Flow Margin 5YEAR AVG | 21.22 |
| Net Profit Margin | 0.2 |
| Net Profit Margin - 5YEAR AVRG. | 0.2 |
| Equity Productivity | 1.08 |
| Return on Equity (ROE) | 0.2 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.2 |
| Capital Invested Productivity | 0.64 |
| Return on Capital Invested (ROCI) | 0.2 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 0.2 |
| Assets Productivity | 0.70 |
| Return on Assets (ROA) | 0.1 |
| Return on Assets (ROA) - 5YEAR AVRG. | 0.1 |
| Gross Profit Margin | 58.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.6 |
| EBITDA Margin - LTM | 29.2 |
| EBIT Margin - LTM | 24.5 |
| Pre-Tax Profit Margin | 0.3 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.3 |
| Effective Tax Rate | 8.9 |
| Effective Tax Rate - 5YEAR AVRG. | 15.8 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 5,169,609 |
| Revenue per Employee | 423,667 |
| Net Income per Employee | 81,200 |
| Average Collection Period | 5,169,609 |
| Receivables Turnover | 4.9 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 3.3 |
| Inventory/Sales | 12.2 |
| Accounts Payble/Sales | 5.03 |
| Assets/Revenue | 1.43 |
| Net Working Capital Turnover | 2.35 |
| Fixed Assets Turnover | 1.00 |
| Total Assets Turnover | 0.7 |
| Revenue per $ Cash | 2.51 |
| Revenue per $ Plant | 4.78 |
| Revenue per $ Common Equity | 1.08 |
| Revenue per $ Capital Invested | 0.64 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 26.5 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 1.0 |
| Research & Devlopment (R&D) as % of Revenue | 6.5 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 6.5 |
|
|  
| | |  |  | | |
